Taisho Pharmaceutical California Inc.
Taisho Pharmaceutical California Inc., a subsidiary of Taisho Pharmaceutical Co., Ltd., is a prominent player in the pharmaceutical industry, headquartered in the United States. Established in 2005, the company has made significant strides in the development and distribution of over-the-counter (OTC) medications and dietary supplements, focusing on enhancing consumer health and well-being. With a strong operational presence across North America, Taisho Pharmaceutical California is renowned for its innovative products, including pain relief solutions and cold and flu remedies. The company’s commitment to quality and efficacy sets it apart in a competitive market. Notably, Taisho has achieved recognition for its robust research and development initiatives, positioning itself as a trusted name in the healthcare sector.
DitchCarbon Score
How does Taisho Pharmaceutical California Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Taisho Pharmaceutical California Inc.'s score of 0 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Taisho Pharmaceutical California Inc.'s reported carbon emissions
In 2023, Taisho Pharmaceutical California Inc. reported no specific carbon emissions data in kg CO2e. The company has not disclosed any Scope 1, 2, or 3 emissions figures, nor have they set any formal reduction targets or climate pledges. While the absence of detailed emissions data limits the assessment of their carbon footprint, the company does provide insights into their operational intensities related to energy consumption. For instance, their gas consumption intensity is approximately 24,140 tonnes, and coal consumption intensity is about 32,310 tonnes. However, these figures do not directly translate to total emissions without further context. As of now, Taisho Pharmaceutical California Inc. has not established any significant climate commitments or reduction initiatives, which places them in a challenging position within the pharmaceutical industry, where sustainability and carbon reduction are increasingly critical.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Taisho Pharmaceutical California Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
